Thursday, 13 December 2018

Welcome in NeoVanc

NeoVanc project aims at adapting an off-patent medicine to the specific need of paediatric populations: in specific to develop an optimal dosing and monitoring regimen for vancomycin use in preterm neonates and infants under 3 months of age in order to be able to register it for use in this age group with a PUMA. 


This project has been funded with the support of the European Commission under the FP7 programme.

Login:

Reserved Access to the our services for our Partners.

Latest:

10/12/2018 - News & Events

7th General Assembly & 4th Investigators Meeting

On 18th and 19th December 2018 the 7th General Assembly and 4th Investigators meeting of NeoVanc…
Read more
04/09/2018 - News & Events

Over 50% of patients now enrolled!

We are delighted to bring you the news that successful randomisation of over 50% of NeoVanc’s target…
Read more
20/02/2018 - News & Events

We reached 103 randomised patients!

We are thrilled to congratulate all the NeoVanc Investigators and Co-Investigators for having…
Read more

Copyright © NeoVanc | All rights reserved. Read the disclaimer.
This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no: 602041
Call: FP7-HEALTH-2013-INNOVATION-1
Privacy policy | Terms and conditions

E-mail: info@penta-id.org